JP2009539997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539997A5 JP2009539997A5 JP2009515476A JP2009515476A JP2009539997A5 JP 2009539997 A5 JP2009539997 A5 JP 2009539997A5 JP 2009515476 A JP2009515476 A JP 2009515476A JP 2009515476 A JP2009515476 A JP 2009515476A JP 2009539997 A5 JP2009539997 A5 JP 2009539997A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- aliphatic
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 NRSO 2 Inorganic materials 0.000 claims description 301
- 150000001875 compounds Chemical class 0.000 claims description 276
- 125000001931 aliphatic group Chemical group 0.000 claims description 129
- 125000001424 substituent group Chemical group 0.000 claims description 88
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 79
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 71
- 125000000623 heterocyclic group Chemical group 0.000 claims description 67
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 64
- 229910052760 oxygen Inorganic materials 0.000 claims description 61
- 125000005842 heteroatom Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 229910052736 halogen Inorganic materials 0.000 claims description 46
- 150000002367 halogens Chemical class 0.000 claims description 45
- 229910052717 sulfur Inorganic materials 0.000 claims description 42
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000004076 pyridyl group Chemical group 0.000 claims description 21
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 20
- 125000002950 monocyclic group Chemical group 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000002619 bicyclic group Chemical group 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 239000011593 sulfur Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 239000011737 fluorine Substances 0.000 claims description 12
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 12
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical group C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 claims description 10
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 239000002464 receptor antagonist Substances 0.000 claims description 6
- 229940044551 receptor antagonist Drugs 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 206010015150 Erythema Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 230000001624 sedative effect Effects 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 230000001272 neurogenic effect Effects 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 102000004300 GABA-A Receptors Human genes 0.000 claims description 2
- 108090000839 GABA-A Receptors Proteins 0.000 claims description 2
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims description 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims description 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 2
- 229940123134 Nitric oxide inhibitor Drugs 0.000 claims description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 2
- 239000002582 adenosine A1 receptor agonist Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002282 antimigraine agent Substances 0.000 claims description 2
- 229940125684 antimigraine agent Drugs 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960003133 ergot alkaloid Drugs 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 239000000472 muscarinic agonist Substances 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940127240 opiate Drugs 0.000 claims description 2
- 239000003402 opiate agonist Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940075993 receptor modulator Drugs 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 239000000085 vanilloid receptor antagonist Substances 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 101800004538 Bradykinin Proteins 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 1
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 206010027603 Migraine headaches Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 0 CCC(C)*1(CC)OC=CNC1=O Chemical compound CCC(C)*1(CC)OC=CNC1=O 0.000 description 16
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
- 229940077122 Adenosine A1 receptor agonist Drugs 0.000 description 1
- ROLKWHSWLJWANC-UHFFFAOYSA-N CN(Cc(cccc1)c1N1)S1(=O)=O Chemical compound CN(Cc(cccc1)c1N1)S1(=O)=O ROLKWHSWLJWANC-UHFFFAOYSA-N 0.000 description 1
- LWFIJQAZZLYLLF-UHFFFAOYSA-N CN(Cc1c(N2)nccc1)C2O Chemical compound CN(Cc1c(N2)nccc1)C2O LWFIJQAZZLYLLF-UHFFFAOYSA-N 0.000 description 1
- PYEHNKXDXBNHQQ-UHFFFAOYSA-N CN(c1ccccc1N1)C1=O Chemical compound CN(c1ccccc1N1)C1=O PYEHNKXDXBNHQQ-UHFFFAOYSA-N 0.000 description 1
- WODAVTOOZDITCO-UHFFFAOYSA-N C[IH]N(Cc(cccc1)c1N1)C1=O Chemical compound C[IH]N(Cc(cccc1)c1N1)C1=O WODAVTOOZDITCO-UHFFFAOYSA-N 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940125794 sodium channel blocker Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81317806P | 2006-06-13 | 2006-06-13 | |
| US60/813,178 | 2006-06-13 | ||
| PCT/US2007/013896 WO2007146349A2 (en) | 2006-06-13 | 2007-06-13 | Cgrp receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539997A JP2009539997A (ja) | 2009-11-19 |
| JP2009539997A5 true JP2009539997A5 (https=) | 2011-07-07 |
| JP5382799B2 JP5382799B2 (ja) | 2014-01-08 |
Family
ID=38832524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515476A Expired - Fee Related JP5382799B2 (ja) | 2006-06-13 | 2007-06-13 | Ｃｇｒｐ受容体アンタゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2027106A2 (https=) |
| JP (1) | JP5382799B2 (https=) |
| CN (1) | CN101501009A (https=) |
| AR (1) | AR061362A1 (https=) |
| AU (1) | AU2007258294A1 (https=) |
| CA (1) | CA2655085A1 (https=) |
| IL (1) | IL195807A0 (https=) |
| MX (1) | MX2008015906A (https=) |
| NZ (1) | NZ574097A (https=) |
| TW (1) | TW200813019A (https=) |
| WO (1) | WO2007146349A2 (https=) |
| ZA (1) | ZA200810791B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834000B2 (en) * | 2006-06-13 | 2010-11-16 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
| JP5451646B2 (ja) * | 2008-02-27 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤 |
| JP5923375B2 (ja) * | 2012-04-24 | 2016-05-24 | 花王株式会社 | Ｃｇｒｐ応答性促進剤 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| JO3669B1 (ar) * | 2015-01-06 | 2020-08-27 | Ferring Bv | بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين |
| WO2019112024A1 (ja) * | 2017-12-08 | 2019-06-13 | キッセイ薬品工業株式会社 | ピロリジン化合物 |
| EP3740477A1 (en) | 2018-01-19 | 2020-11-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| US20210121541A1 (en) * | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
| US20210130445A1 (en) * | 2019-07-05 | 2021-05-06 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| EP4731613A1 (en) * | 2023-06-21 | 2026-04-29 | Valo Health, Inc. | Spirocyclic parp inhibitors and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52552B (sr) * | 2002-06-05 | 2013-04-30 | Bristol-Myers Squibb Company | Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom |
| TW200412948A (en) * | 2002-08-23 | 2004-08-01 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| EP1641423B1 (en) * | 2003-06-26 | 2010-03-17 | Merck Sharp & Dohme Corp. | Benzodiazepine cgrp receptor antagonists |
-
2007
- 2007-06-13 EP EP07796082A patent/EP2027106A2/en not_active Withdrawn
- 2007-06-13 MX MX2008015906A patent/MX2008015906A/es active IP Right Grant
- 2007-06-13 CA CA002655085A patent/CA2655085A1/en not_active Abandoned
- 2007-06-13 AR ARP070102587A patent/AR061362A1/es unknown
- 2007-06-13 JP JP2009515476A patent/JP5382799B2/ja not_active Expired - Fee Related
- 2007-06-13 AU AU2007258294A patent/AU2007258294A1/en not_active Abandoned
- 2007-06-13 ZA ZA200810791A patent/ZA200810791B/xx unknown
- 2007-06-13 CN CNA2007800297374A patent/CN101501009A/zh active Pending
- 2007-06-13 WO PCT/US2007/013896 patent/WO2007146349A2/en not_active Ceased
- 2007-06-13 NZ NZ574097A patent/NZ574097A/en not_active IP Right Cessation
- 2007-06-13 TW TW096121362A patent/TW200813019A/zh unknown
-
2008
- 2008-12-09 IL IL195807A patent/IL195807A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539997A5 (https=) | ||
| AP1122A (en) | Therapeutically active compounds based on based on based on indazole bioisostere replacement of catechol in PDE4 inhibitors. | |
| EP2400962B1 (de) | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids | |
| EP3674298B9 (de) | Substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln | |
| US6271390B1 (en) | Suppression of the IgE-dependent allergic response by benzimidazole analogs | |
| CN111094255B (zh) | 具有环状结构的化合物 | |
| JP6232429B2 (ja) | ＲＯＲγＴ阻害剤としての３−シクロヘキセニルおよびシクロヘキシル置換インドールおよびインダゾール化合物およびそれらの使用 | |
| EP2555774B1 (de) | Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten | |
| EP4031240A1 (en) | New compounds | |
| JP2017528494A (ja) | ｓＧＣ刺激剤 | |
| KR20140107574A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| WO2008076415A1 (en) | Methods of using mek inhibitors | |
| JP2015526442A (ja) | ＲＯＲγＴ阻害剤としてのＮ−アルキル化インドールおよびインダゾール化合物およびそれらの使用 | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2006522747A (ja) | 縮合１，２，４−トリアゾールの薬学的使用 | |
| JP2013503139A (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| CN104136428A (zh) | 用于抑制bcl2与结合配偶体相互作用的化合物 | |
| US20240174657A1 (en) | Selective angiotensin ii receptor ligands | |
| CA3251567A1 (en) | ARYLALKYNAMIDE DERIVATIVES | |
| WO2022200785A1 (en) | Selective angiotensin ii receptor ligands | |
| JP2012507547A (ja) | 脳マラリアの治療のためのｓ１ｐリアーゼ阻害剤 | |
| HK40023323A (en) | Compound having cyclic structure |